Better Value & Growth: BSX Leads Stryker Stock
BSX is Stryker’s peer in Health Care Equipment industry that has:
1) Lower valuation (P/OpInc) compared to Stryker stock
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying BSX stock vs. SYK stock
Individual stocks can be volatile and shake you out, but strategic allocation and diversification helps you stay invested. Our Boston-based, wealth management partner’s asset allocation approach is designed exactly for that.
- Stocks, Bonds, Gold, Crypto: Market Update 3/31/2026
- Is Uber Technologies Stock Undervalued Stock Or Value Trap?
- Exxon Mobil Stock On A Winning Streak: Time To Get In Or Book Profits?
- Why Chevron Stock Jumped 40%?
- Why Investors Keep Buying PLTR Stock?
- Can Boston Scientific Stock Surge 40% From Here?
Key Metrics Compared
| Metric | SYK | BSX |
|---|---|---|
| P/OpInc* | 24.7x | 23.5x |
| LTM OpInc Growth | 8.4% | 32.4% |
| 3Y Avg OpInc Growth | 17.8% | 25.1% |
| LTM Revenue Growth | 11.2% | 19.9% |
| 3Y Avg Revenue Growth | 10.8% | 16.6% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
But do these numbers tell the full story? Read Buy or Sell SYK Stock to see if Stryker still has an edge that holds up under the hood. As a quick background, Stryker (SYK) provides surgical equipment, navigation systems, patient care products, and implants for hip, knee, trauma, and extremities surgeries through MedSurg and Orthopaedics segments.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if Stryker stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for Stryker in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for Stryker would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | SYK | BSX |
|---|---|---|
| P/OpInc* | 29.5x | 40.2x |
| LTM OpInc Growth | 8.2% | 31.6% |
| 3Y Avg OpInc Growth | 19.0% | 23.4% |
| LTM Revenue Growth | 11.0% | 21.6% |
| 3Y Avg Revenue Growth | 10.8% | 15.6% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | SYK | BSX |
|---|---|---|
| P/S | 5.0x | 4.6x |
| Market Cap (Current) | $ 124.7 Bil | $ 93.3 Bil |
| LTM Revenue | $ 25.12 Bil | $ 20.07 Bil |
| LTM Opinc | $ 5.06 Bil | $ 3.97 Bil |
| LTM Op Margin | 20.1% | 19.8% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the its benchmark – a combination of S&P 500, Russell, and S&P midcap index.